Irritation and Sensitization Potential of Repeat Applications of Rotigotine Patch

NCT02727205 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

260

Enrollment

INDUSTRY

Sponsor class

Conditions

Bioequivalence - Irritation and Sensitization Potential of Transdermal Patch

Interventions

DRUG: Rotigotine Transdermal System

Sponsor

Inflamax Research Incorporated